Growth hormone added lean mass in trials while strength stayed flat

Does growth hormone increase strength?

No. Growth hormone did not improve muscle strength in placebo-controlled trials of healthy young adults, even as their lean mass rose ^[1]⁠^[4].

The strongest evidence is a 2017 meta-analysis of 11 placebo-controlled trials in 254 healthy young subjects. Over weeks to months of dosing, growth hormone produced no improvement in muscle strength (p=0.36) or maximal oxygen uptake (p=0.89), the standard endurance marker ^[1]. An earlier, larger 2008 systematic review found that strength and exercise capacity "did not seem to improve" despite a 2.1 kg lean-mass gain ^[4].

A 2024 umbrella review pooling systematic reviews across several performance-enhancing drugs reached the same conclusion independently: growth hormone alters body composition without a strength or performance benefit ^[2]. Anabolic steroids, in the same literature, produced a 5% to 52% strength increase ^[2].

Three independent syntheses, with different search windows and overlapping but not identical study sets, land on the same dissociation. For sports pharmacology, that convergence is about as solid as the evidence gets. A 2011 review in an endocrinology journal summarized the evidence the same way: growth hormone does not enhance strength, power or aerobic capacity ^[7].

Adding testosterone barely changes the picture. In a trial of healthy elderly men, growth hormone plus testosterone increased midthigh muscle cross-sectional area (p=0.006), yet only one of six strength measures moved significantly ^[11]. If a targeted androgen boost layered on growth hormone barely nudges strength, growth hormone alone doing nothing to strength is not an anomaly. It is the expected result across every design tested.

Does growth hormone add lean mass?

Yes. Across independent systematic reviews in different populations, exogenous growth hormone increases lean body mass by a consistent amount.

In young, generally healthy adults, a 2008 systematic review covering 27 study samples, 303 participants and 13.3 person-years of treatment found that lean body mass rose by 2.1 kg (95% CI, 1.3 to 2.9 kg) relative to controls ^[4]. The 2017 meta-analysis of 254 subjects found the same direction: lean body mass up and fat mass down, both p<0.01 ^[1].

In healthy older adults, a review pooling 31 studies and 220 growth hormone recipients, with a mean age of 69, found comparable body composition shifts ^[9]. A dedicated RCT in men aged 65 to 80 confirmed lean body mass increases with growth hormone alone (p=0.004) and with growth hormone plus testosterone (p=0.008) ^[11].

The lean-mass gain is the part of the story that anti-aging marketing gets right, and it is the only part.

Why does growth hormone add lean mass without adding strength?

Body-composition scans cannot separate contractile muscle from retained water and connective tissue, and growth hormone causes fluid retention, so lean mass can rise while strength stays flat.

Growth hormone acts on its receptor in liver and peripheral tissue. Its anabolic signal runs mostly through IGF-I, which growth hormone stimulates the liver and other tissues to release, and IGF-I promotes protein synthesis. Growth hormone also promotes lipolysis, acts directly on the kidneys and vasculature to retain sodium and shift fluid into the extracellular and intracellular space, and stimulates collagen turnover in tendon, skin and connective tissue. None of this is controversial endocrinology.

Lean body mass measured by DEXA or bioimpedance is not a direct readout of muscle protein content. The measurement captures water, connective tissue, organ mass and skeletal muscle together. Growth hormone's sodium and water retention plus collagen synthesis give a plausible route to raising that composite number without adding meaningful contractile tissue, and strength depends on contractile tissue.

The trial data support that reading indirectly. In a four-week trial of growth hormone and IGF-I in elderly women, the groups with the largest lean-mass gains also reported joint swelling, bloating, headaches, and an intracellular fluid increase that approached significance ^[6]. Edema and arthralgia, the clinical signature of fluid shift and connective-tissue turnover, show up disproportionately in the same trials where lean mass rises ^[9]⁠^[2]. Fluid retention, rather than new muscle protein, is a plausible explanation for a substantial share of the lean-mass rise ^[7].

None of the trials cited below directly measured muscle protein fractional synthetic rate, so the composite explanation is the best available inference from composition and outcome data, not a confirmed mechanism traced at the protein level. The negative result is firmer: whatever drives the lean-mass number, it has not translated into force output in any trial design tested so far.

Does growth hormone improve sprint or endurance performance?

Growth hormone had no measurable effect on endurance or VO2max ^[1]⁠^[4]. Its only performance effect is narrow: anaerobic, sprint-type capacity improved by a few percent in the single study that measured it ^[1]⁠^[7].

The 2017 meta-analysis found a significant increase in anaerobic exercise capacity (p<0.01), but that result came from the one included study that measured it, so it stands as a hypothesis for future testing rather than an established effect ^[1]. A 2011 review concluded that growth hormone does improve anaerobic exercise capacity ^[7]. Even at supraphysiological trial doses, the change was a modest, few-percent improvement in short, high-intensity output, not a change in maximal force ^[1]⁠^[7].

Growth hormone's most consistent, well-documented effect is metabolic, not contractile. Growth hormone raises circulating IGF-1, increases lipolysis, and during exercise raises glycerol and free fatty acid levels, so more fat is mobilized into the bloodstream while working out ^[1]. The respiratory quotient during exercise was unchanged in pooled trial data, so despite more circulating fatty acids, the body did not visibly shift its fuel mix ^[1]. Whatever is happening with sprint-type output is not a straightforward "better fat burning, more energy" story.

Strength depends on how much force a muscle fiber can generate, which depends on fiber cross-sectional area and neuromuscular recruitment, and both are stubbornly resistant to growth hormone in controlled trials ^[1]⁠^[4]. Sprint or anaerobic capacity draws on the phosphagen and glycolytic systems, on tendon and connective tissue stiffness, and on how quickly force can be produced and transmitted, not just how much force exists in reserve.

A hormone that changes fluid dynamics, connective tissue hydration or tendon elasticity could plausibly shift short, explosive, anaerobic output without touching maximal force capacity or oxidative endurance. That idea is a mechanistic hypothesis, not an established pathway. No study traces the sprint effect to a specific tissue-level cause, so it remains plausible speculation rather than settled physiology.

What doses did the growth hormone trials use?

The athletic-performance trials used a mean growth hormone dose of about 36 micrograms per kilogram per day, for a mean of about 20 days when dosing extended beyond a single day ^[4]. These are supraphysiological, injected doses under trial supervision, well above normal endogenous output. Even at that dose, strength stayed flat (p=0.36) while lean mass rose meaningfully ^[1].

Trials in healthy elderly adults, often the population cited in longevity marketing, used a lower mean dose of about 14 micrograms per kilogram per day, over a mean of 27 weeks ^[9]. Orthopedic clinical research using recombinant growth hormone for bone and soft tissue healing reported a mean dose around 1.49 milligrams per day, in patients with a mean age in the mid-fifties ^[3]. That is a different unit scale and a different population entirely.

None of these figures describes what a typical outpatient peptide clinic prescribes today, and none of the studies cited below quantifies clinic dosing. Citing a research trial's sprint-capacity finding to justify a low-dose recovery or longevity protocol is an extrapolation the data do not support.

Do studies in hormone-deficient patients apply to healthy people?

No. Replacement trials describe correcting a diagnosed deficit in older or clinically deficient patients, a different physiological starting point from a healthy athlete with normal growth hormone output.

A separate literature studies growth hormone replacement in adults with a diagnosed pituitary deficiency, and it is often cited as if it applied to healthy people. In one such trial, 31 patients aged 60 to 79 with multiple pituitary hormone deficiencies received growth hormone or placebo for six months. Lean body mass rose and correlated with the increase in IGF-I, and bone metabolism markers improved ^[5].

A 2026 systematic review of growth hormone used therapeutically in orthopaedic contexts, in an older population with a mean age of 54, found dose-dependent changes in lean mass and bone healing ^[3]. Those findings are real. Applying a replacement-therapy result to justify use in someone who is not deficient answers a different question from the one the athlete trials tested ^[5]⁠^[3].

What are the side effects of growth hormone?

Soft tissue edema, arthralgia, carpal tunnel symptoms, gynecomastia and impaired fasting glucose occurred substantially more often in growth hormone recipients than controls in a 2007 systematic review ^[9]. The 2024 umbrella review across performance-enhancing drug classes echoed the same cluster: soft tissue edema, fatigue, arthralgias and carpal tunnel syndrome as the recognized growth hormone risk profile, alongside its finding of no strength or performance benefit ^[2].

Consumer-facing coverage of the Rudman-era lean-mass story routinely omits this side of the data. The omission matters because both findings come from the same trials: the dosing that produced the mass gain also produced the elevated adverse event rate.

Do growth hormone secretagogues reproduce these effects?

Secretagogues have no established data pathway to a better strength outcome, because growth hormone itself does not move strength in the healthy adults secretagogues target.

Secretagogues are marketed on the premise that stimulating the body's own GH pulses will recreate the benefits attributed to exogenous growth hormone. The performance trials tested the parent hormone directly, at controlled and in several cases supraphysiologic doses, in that same healthy-adult population. A secretagogue produces a smaller, more physiological rise in GH and IGF-1. The conclusion is a reasoning bridge from the growth hormone trials, not a direct finding, since none of the performance trials tested a secretagogue against these endpoints.

Oral ghrelin receptor agonists such as MK-0677, a common non-injectable alternative marketed for raising growth hormone activity, raise IGF-1 substantially: about 65% higher than placebo in one randomized crossover trial ^[10]. That trial was conducted in hemodialysis patients for a nutritional endpoint and did not measure athletic performance at all ^[10]. Raising a hormone number is not the same as producing the specific, narrow effect seen in the direct performance trials, and none of the trials cited below shows that secretagogues reproduce even the sprint-specific finding. Compound-level evidence is covered in the MK-0677 evidence review, the GHRP-2 evidence review and the ipamorelin evidence review.

What is still unknown about growth hormone and performance?

Long-term effects, the sprint mechanism and stacked use with other agents remain unresolved:

• Duration. The controlled trials are short, mostly weeks rather than years, so both the sprint-capacity effect and the lean-mass gain are measured over a limited window ^[1]⁠^[4].
• Years of doping-level use. No placebo-controlled data in healthy adults cover what sustained, doping-relevant dosing does over years. Review literature raises the concern that prolonged growth hormone excess can produce a state resembling acromegaly, a condition associated with increased morbidity, but that concern is extrapolated from growth hormone excess generally, not from a long-term athlete trial ^[7]⁠^[8].
• The sprint mechanism. Why anaerobic capacity improved, whether through fluid effects on tissue mechanics, altered fuel availability or another pathway, is not established. The evidence shows a small effect in one study, not its mechanism ^[1]⁠^[7].
• Stacking. Much of the doping-detection literature was not designed to separate growth hormone's own effect from the anabolic steroids or insulin that real-world users often combine it with. The isolated effect size is reasonably well established, but the effect of growth hormone stacked with other agents is not, and whether it adds anything on top of steroids or insulin remains outside what placebo-controlled trials have tested ^[8].